RESUMO
The pathogenesis of recurrent acute tonsillitis (Rtn) is to be further investigated. Polymorphonuclear neutrophils (PMN) often associate with the pathogenesis of acute and chronic inflammation. This study aims to identify the antigen-specific PMNs (sPMNs) isolated from the tonsillar tissues with recurrent acute inflammation. In this study, CD66b+ PMNs were isolated from surgically removed tonsils (40 tonsils were from 20 Rtn patients; 24 tonsils were from 12 tonsil tumour patients) by flow cytometry cell sorting. sPMNs were identified through immunological approaches. We found that compared with the control tonsil samples (from marginal non-tumour tissues of tonsil cancer), Rtn samples showed higher PMN frequency, higher levels of myeloperoxidase (MPO) and neutrophil elastase (NE), in which positive correlation was detected between the inflammatory scores in the Rtn tissues and PMN counts (r = .7352; p = .0002), or MPO (r = .6565, p = .0017), or NE (r = .6687, p = .0013). Upon exposure to tonsillar tissue protein extracts in the culture, a portion of Rtn PMNs was activated and released inflammatory mediators. A complex of tonsillar tissue-specific IgG and FcγRI was observed on the surface of Rtn PMNs; these PMNs could specifically recognize the Rtn tissue extracts and were designated the tonsillar antigen-specific PMNs (sPMNs). A signal transduction pathway of mitogen-activated protein kinase (MAPK)-nuclear factor of T cell activation (NFAT) was activated in sPMNs after exposure to Rtn tissue extracts. In summary, a fraction of sPMN in the Rtn tonsillar tissues was identified and characterized. The sPMNs can be activated upon exposure to tonsil-specific antigens. These sPMNs may contribute to the Rtn pathogenesis.
Assuntos
Antígenos/imunologia , Neutrófilos/imunologia , Tonsila Palatina/imunologia , Tonsilite/imunologia , Adolescente , Adulto , Idoso , Animais , Extratos Celulares/imunologia , Medicamentos de Ervas Chinesas/farmacologia , Feminino , Humanos , Mediadores da Inflamação/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Pessoa de Meia-Idade , Neutrófilos/efeitos dos fármacos , Tonsila Palatina/efeitos dos fármacos , Peroxidase/metabolismo , Receptores de IgG/imunologia , Recidiva , Adulto JovemRESUMO
BACKGROUND: Recurrent tonsillitis might reduce the immunological capability of fighting against the infection of tonsil tissue. Polypodium leucotomos (Anapsos) immunomodulating effect has been subject of research in the last years. The aim of this research is to test the in vitro immunomodulating capacity of Anapsos in a child palatine tonsil explants model. METHODS: Palatine tonsils explants of children undergoing amigdalectomy were stimulated with mononuclear cells obtained from their own blood by density gradient centrifugation. Some were then treated with Anapsos while others rest untreated. Cytokines were measured by ELISA, immune cells activation was measured by flow cytometry and activation of immunoglobulins was appreciated by indirect immunofluorescence in tonsils tissue. RESULTS: Anapsos activates Natural Killers cells. It increases IL-2 and IFN-γ levels by the activation of Th2 lymphocytes, and IL-10, by the Th1 lymphocytes. Anapsos also increases immunoglobulins IgM, IgD and IgG4 by B-lymphocyte activation in tonsils tissue. CONCLUSION: Anapsos has an immunomodulating effect, both in humoral and cellular responses, which might benefit children suffering of recurrent tonsillitis as it could enhance their immune system. This effect might reduce the number of episodes suffered and therefore the number of children undergoing surgery.
Assuntos
Citocinas/metabolismo , Glicosídeos/imunologia , Imunoglobulinas/metabolismo , Fatores Imunológicos/uso terapêutico , Leucócitos Mononucleares/imunologia , Tonsila Palatina/efeitos dos fármacos , Tonsilite/tratamento farmacológico , Técnicas de Cultura de Células , Criança , Pré-Escolar , Ensaio de Imunoadsorção Enzimática , Feminino , Citometria de Fluxo , Imunofluorescência , Humanos , Leucócitos Mononucleares/metabolismo , Tonsila Palatina/imunologia , Tonsila Palatina/metabolismo , Polypodium , Tonsilectomia , Tonsilite/imunologia , Tonsilite/cirurgiaRESUMO
Tonsil-derived (T-) mesenchymal stem cells (MSCs) display mutilineage differentiation potential and self-renewal capacity and have potential as a banking source. Diabetes mellitus is a prevalent disease in modern society, and the transplantation of pancreatic progenitor cells or various stem cell-derived insulin-secreting cells has been suggested as a novel therapy for diabetes. The potential of T-MSCs to trans-differentiate into pancreatic progenitor cells or insulin-secreting cells has not yet been investigated. We examined the potential of human T-MSCs to trans-differentiate into pancreatic islet cells using two different methods based on ß-mercaptoethanol and insulin-transferin-selenium, respectively. First, we compared the efficacy of the two methods for inducing differentiation into insulin-producing cells. We demonstrated that the insulin-transferin-selenium method is more efficient for inducing differentiation into insulin-secreting cells regardless of the source of the MSCs. Second, we compared the differentiation potential of two different MSC types: T-MSCs and adipose-derived MSCs (A-MSCs). T-MSCs had a differentiation capacity similar to that of A-MSCs and were capable of secreting insulin in response to glucose concentration. Islet-like clusters differentiated from T-MSCs had lower synaptotagmin-3, -5, -7, and -8 levels, and consequently lower secreted insulin levels than cells differentiated from A-MSCs. These results imply that T-MSCs can differentiate into functional pancreatic islet-like cells and could provide a novel, alternative cell therapy for diabetes mellitus.
Assuntos
Transdiferenciação Celular , Técnicas de Reprogramação Celular , Células Secretoras de Insulina/citologia , Células-Tronco Mesenquimais/citologia , Tonsila Palatina/citologia , Tecido Adiposo/citologia , Animais , Terapia Baseada em Transplante de Células e Tecidos , Células Cultivadas , Diabetes Mellitus Experimental/cirurgia , Humanos , Insulina/farmacologia , Células Secretoras de Insulina/transplante , Mercaptoetanol/farmacologia , Células-Tronco Mesenquimais/metabolismo , Camundongos , Tonsila Palatina/efeitos dos fármacos , Selênio/farmacologia , Sinaptotagminas/deficiência , Transferrina/farmacologiaRESUMO
OBJECTIVE: Post-tonsillectomy pain is believed to be mediated by noxious stimulation of C-fiber afferents located in the peritonsillary space, and local anesthetic infiltration to this area may decrease pain by blocking the sensory pathways and thus preventing the nociceptive impulses. We aimed to compare the effects of different concentrations of preincisional peritonsillar levobupivacaine (0.25% and 0.5%) infiltration on postoperative pain and bleeding in a placebo-controlled design. PATIENTS AND METHODS: After obtaining Institutional Ethics Committee approval, 72 ASA I-II patients between 3 and 12 years of age, scheduled to undergo tonsillectomy were enrolled and randomly assigned to one of the three groups using the sealed envelope technique, as Group I (Control group), Group II, and Group III receiving preincisional bilateral peritonsillar infiltration with saline, 0.25% levobupivacaine and 0.5% levobupivacaine, respectively (3 mL to each tonsil). Pain, fever, dysphagia; nausea-vomiting and hemorrhage were evaluated at postoperative 0, 30, and 60 minutes and 2, 6, 12, and 24 hours. Oral paracetamol was administered at a dose of 15 mg/kg when FLACC score was > 4. The number of paracetamol administrations within the first 24 hours were recorded. RESULTS: The patients in Groups I, II and III defined pain (FLACC > 4) at a rate of 87%, 60.9%, and 54.2% within the postoperative first 24 hours, respectively. The total number of additional analgesic requirements was significantly low in Group II and III when compared with Group I. There was no difference between groups in terms of fever, dysphagia, nausea-vomiting, hemorrhage. CONCLUSIONS: Both concentrations (0.50% and 0.25%) of levobupivacaine were found to be equally safe and effective during preincisional peritonsillar infiltration in children. NCT number: 02322346.
Assuntos
Anestesia Local/métodos , Bupivacaína/análogos & derivados , Manejo da Dor/métodos , Dor Pós-Operatória/prevenção & controle , Tonsila Palatina/cirurgia , Tonsilectomia/efeitos adversos , Anestésicos Locais/administração & dosagem , Bupivacaína/administração & dosagem , Criança , Pré-Escolar , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Humanos , Levobupivacaína , Masculino , Dor Pós-Operatória/diagnóstico , Tonsila Palatina/efeitos dos fármacosRESUMO
Although more-recently developed antivirals target different molecules in the HIV-1 replication cycle, nucleoside reverse transcriptase inhibitors (NRTIs) remain central for HIV-1 therapy. Here, we test the anti-HIV activity of a phosphonate chimera of two well-known NRTIs, namely AZT and 3TC. We show that this newly synthesized compound suppressed HIV-1 infection in lymphoid tissue ex vivo more efficiently than did other phosphonates of NRTIs. Moreover, the new compound was not toxic for tissue cells, thus making the chimeric phosphonate strategy a valid approach for the development of anti HIV-1 compound heterodimers.
Assuntos
Fármacos Anti-HIV/farmacologia , Didesoxinucleotídeos/farmacologia , Infecções por HIV/virologia , HIV-1/efeitos dos fármacos , Lamivudina/farmacologia , Tonsila Palatina/efeitos dos fármacos , Nucleotídeos de Timina/farmacologia , Zidovudina/análogos & derivados , Fármacos Anti-HIV/síntese química , Fármacos Anti-HIV/química , Didesoxinucleotídeos/química , Avaliação Pré-Clínica de Medicamentos , Infecções por HIV/tratamento farmacológico , HIV-1/fisiologia , Humanos , Técnicas In Vitro , Lamivudina/química , Tonsila Palatina/virologia , Nucleotídeos de Timina/química , Replicação Viral/efeitos dos fármacos , Zidovudina/química , Zidovudina/farmacologiaRESUMO
The purpose of this study was to investigate the effects of dietary NiCl2 on antioxidant function, apoptosis, and the protein expression, mRNA expression and contents of the bcl-2, bax and caspase-3 in the cecal tonsil of broilers. 280 one-day-old avian broilers were divided into four groups and fed on a corn-soybean basal diet as control diet or the same basal diet supplemented with 300, 600 and 900 mg/kg of NiCl2 for 42 days. The activities of SOD, CAT and GSH-Px, and the ability to inhibit hydroxy radical, and GSH content were significantly decreased in all experimental groups. MDA content was significantly increased. The protein expression, mRNA expression and contents of bcl-2 were decreased, and bax and caspase-3 were increased in all experimental groups. The percentages of apoptotic lymphocytes were significantly increased. In conclusion, dietary NiCl2 in excess of 300 mg/kg caused oxidative stress, and then induced decreased the protein expression, mRNA expression and the contents of bcl-2, and increased protein expression, mRNA expression and the contents of bax and caspase-3 proteins in the cecal tonsil. The local intestinal mucosal immunity could finally be impaired due to the oxidative stress and apoptosis in the cecal tonsil caused by NiCl2.
Assuntos
Apoptose/efeitos dos fármacos , Caspase 3/genética , Níquel/toxicidade , Estresse Oxidativo/efeitos dos fármacos , Tonsila Palatina/efeitos dos fármacos , Proteína X Associada a bcl-2/genética , Animais , Catalase/metabolismo , Galinhas , Glutationa Peroxidase/metabolismo , Malondialdeído/metabolismo , Tonsila Palatina/enzimologia , Tonsila Palatina/metabolismo , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Superóxido Dismutase/metabolismoRESUMO
BACKGROUND: Adenotonsillar hypertrophy (ATH) is a frequent cause of upper airways obstructive syndromes associated to middle ear and paranasal sinuses disorders, swallowing and voice disorders, sleep quality disorders, and occasionally facial dysmorphisms. ATH treatment is essentially based on a number of medical-surgical aids including nasal irrigation with topical antibiotics and corticosteroids and/or treatment with systemic corticosteroids, immunoregulators, thermal treatments, adenotonsillectomy, etc. OBJECTIVES: The aim of the present study is to assess the efficacy of Aerosal halotherapy in the treatment of sub-obstructive adenotonsillar disease and correlated conditions compared to placebo treatment. METHODS: A total of 45 patients with sub-obstructive adenotonsillar hypertrophy were randomized to receive either Aerosal halotherapy or placebo for 10 treatment sessions. The main outcome was a reduction greater than or equal to 25% from the baseline of the degree of adenoid and/or tonsillar hypertrophy. RESULTS: In the intention-to-treat analysis, a reduction of the degree of adenoid and/or tonsillar hypertrophy ≥25% from baseline after 10 therapy sessions was found in 44.4% of the patients in the halotherapy arm and in 22.2% of the patients in the placebo arm (P=0.204). Among the secondary outcomes, the reduction of hearing loss after 10 treatment sessions in the halotherapy arm was higher than the placebo arm (P=0.018) as well as the time-dependent analysis showed significantly improved peak pressure in the Aerosal group (P=0.038). No side effects were reported during the trial. In addition, the therapy was well accepted by the young patients who considered it as a time for play rather than a therapy. CONCLUSIONS: Aerosal halotherapy can be considered a viable adjunct, albeit not a replacement, to conventional medical treatment of sub-obstructive adenotonsillar syndrome and related conditions. Further research is however needed to improve ATH treatment.
Assuntos
Tonsila Faríngea/efeitos dos fármacos , Obstrução das Vias Respiratórias/tratamento farmacológico , Terapias Complementares/métodos , Tonsila Palatina/efeitos dos fármacos , Sais/administração & dosagem , Cloreto de Sódio/administração & dosagem , Tonsila Faríngea/patologia , Administração por Inalação , Obstrução das Vias Respiratórias/etiologia , Obstrução das Vias Respiratórias/fisiopatologia , Distribuição de Qui-Quadrado , Criança , Pré-Escolar , Método Duplo-Cego , Feminino , Seguimentos , Humanos , Hipertrofia/tratamento farmacológico , Hipertrofia/patologia , Itália , Masculino , Sprays Nasais , Tonsila Palatina/patologia , Estudos Prospectivos , Valores de Referência , Resultado do TratamentoRESUMO
Epstein-Barr virus (EBV) may cause a variety of virus-associated diseases, but no antiviral agents have yet been developed against this virus. Animal models are thus indispensable for the pathological analysis of EBV-related infections and the elucidation of therapeutic methods. To establish a model system for the study of EBV infection, we tested the ability of B95-8 virus and recombinant EBV expressing enhanced green fluorescent protein (EGFP) to replicate in human lymphoid tissue. Human tonsil tissues that had been surgically removed during routine tonsillectomy were sectioned into small blocks and placed on top of collagen sponge gels in culture medium at the air-interface, then a cell-free viral suspension was directly applied to the top of each tissue block. Increasing levels of EBV DNA in culture medium were observed after 12-15 days through 24 days post-infection in tissue models infected with B95-8 and EGFP-EBV. Expression levels of eight EBV-associated genes in cells collected from culture medium were increased during culture. EBV-encoded small RNA-positive cells were detected in the interfollicular areas in paraffin-embedded sections. Flow cytometric analyses revealed that most EGFP(+) cells were CD3(-) CD56(-) CD19(+) HLA-DR(+), and represented both naïve (immunoglobulin D(+)) and memory (CD27(+)) B cells. Moreover, EBV replication in this model was suppressed by acyclovir treatment in a dose-dependent manner. These data suggest that this model has potential for use in the pathological analysis of local tissues at the time of primary infection, as well as for screening novel antiviral agents.
Assuntos
Técnicas de Cultura de Células/métodos , Herpesvirus Humano 4/fisiologia , Tonsila Palatina/citologia , Tonsila Palatina/virologia , Replicação Viral , Aciclovir/farmacologia , Antivirais/farmacologia , Separação Celular , Avaliação Pré-Clínica de Medicamentos , Proteínas de Fluorescência Verde/genética , Herpesvirus Humano 4/efeitos dos fármacos , Herpesvirus Humano 4/genética , Humanos , Linfócitos/citologia , Linfócitos/efeitos dos fármacos , Linfócitos/virologia , Tonsila Palatina/efeitos dos fármacos , Replicação Viral/efeitos dos fármacosRESUMO
OBJECTIVE: To assess the effect on postoperative pain after local application of bupivacaine in the tonsillar fossa. METHODS: Seventy two patients were recruited in this prospective single blind controlled trial. There were 45 females and 27 males between the ages of 7 and 35 years. After tonsillectomy the right tonsillar fossae (subject fossae) were packed with tonsillar gauze soaked in 2 mls of 0.5% Abbocaine (bupivacaine) solution and kept in situ for five minutes. The left fossae (control fossae) were packed with the similar tonsillar swab soaked in 0.9% normal saline. RESULTS: The main outcome measure was severity of pain by using visual analogue score. The measurements were taken at various intervals, i.e. after 4 hours, before bed, before breakfast, before lunch and before discharge. The mean post-operative pain scores for the subject fossa after 4 hours, before bed, before breakfast, before lunch and before discharge were 3.09 (+/- 0.85), 3.25 (+/- 0.64), 2.89 (+/- 0.72), 2.47 (+/- 0.67) and 2.37 (+/- 0.57) respectively. The mean post-operative pain scores for control fossa after 4 hours, before bed, before breakfast, before lunch and before discharge were 5.78 (+/- 1.51), 5.50 (+/- 1.29), 4.34 (+/- 1.13), 3.29 (+/- 0.91) and 2.73 (+/- 0.81) respectively. There was significant difference between subject and control fossae scores at all the stages up to discharge of patients, showing better pain relief with bupivacaine. CONCLUSION: Topical application of bupivacaine to the tonsillar fossa can reduce post-operative pain and facilitate early eating and drinking during the post-operative period.
Assuntos
Anestesia Local/métodos , Anestésicos Locais/administração & dosagem , Bupivacaína/administração & dosagem , Dor Pós-Operatória/prevenção & controle , Tonsila Palatina/efeitos dos fármacos , Tonsilectomia/efeitos adversos , Adolescente , Adulto , Criança , Feminino , Humanos , Masculino , Estudos Prospectivos , Método Simples-Cego , Resultado do TratamentoRESUMO
Absinthe, an abused drug in the early 1900s, has been speculated to activate the receptors responsible for marijuana intoxication (the CB1 cannabinoid receptor) (Nature 253:365-356; 1975). To test this hypothesis, we investigated oil of wormwood (Artemisia absinthium) the active plant product found in absinthe, and thujone, the active compound found in oil of wormwood. Radioligand receptor binding assays employing membrane preparations from rat brains containing CB1 cannabinoid receptors, and human tonsils containing CB2 receptors, demonstrated that thujone displaced [3H]CP55940, a cannabinoid agonist, only at concentrations above 10 microM. HPLC analysis of oil of wormwood revealed that only the fractions having mobility close to thujone displaced [3H]CP55940 from the CB1 cannabinoid receptor. [35S]GTPgammaS binding assays revealed that thujone failed to stimulate G-proteins even at 0.1 mM. Thujone failed to inhibit forskolin-stimulated adenylate cyclase activity in N18TG2 membranes at 1 mM. Rats administered thujone exhibited different behavioral characteristics compared with rats administered a potent cannabinoid agonist, levonantradol. Therefore, the hypothesis that activation of cannabinoid receptors is responsible for the intoxicating effects of thujone is not supported by the present data.
Assuntos
Artemisia/química , Canabinoides/farmacologia , Monoterpenos , Plantas Medicinais , Receptor CB2 de Canabinoide , Receptores de Droga/metabolismo , Terpenos/metabolismo , Inibidores de Adenilil Ciclases , Adenilil Ciclases/metabolismo , Animais , Comportamento Animal/efeitos dos fármacos , Monoterpenos Bicíclicos , Ligação Competitiva/efeitos dos fármacos , Química Encefálica/efeitos dos fármacos , Colforsina/farmacologia , Cicloexanóis/farmacologia , Proteínas de Ligação ao GTP/metabolismo , Guanosina 5'-O-(3-Tiotrifosfato)/farmacologia , Humanos , Técnicas In Vitro , Masculino , Tonsila Palatina/efeitos dos fármacos , Tonsila Palatina/metabolismo , Ensaio Radioligante , Ratos , Ratos Sprague-Dawley , Receptores de Canabinoides , Receptores de Droga/agonistas , Receptores de Droga/efeitos dos fármacos , Transdução de Sinais/efeitos dos fármacosRESUMO
Therapeutic effect of liposomal dosages of rifampicin and prodigiozan was studied on rabbits with simulated chronic tonsillitis in comparison to that of commercial ones of the drugs. The treatment schemes included daily intra-tonsillar++ injections of the dosage forms for 5 days. A high efficacy of their liposomal dosage forms in treatment of experimental chronic tonsillitis was confirmed microbiologically and immunologically. Approval of the liposomal dosage forms used in the therapy of patients with chronic tonsillitis requires clinical trials.